期刊文献+

沉渣包埋联合免疫组化在胸水转移性肺腺癌与胸膜恶性间皮瘤鉴别诊断中的应用 被引量:17

Application of immunohistochemistry in differential diagnosis of adenocarcinoma from mesothelioma with paraffin-embedded sediment of plural fluid cytology
下载PDF
导出
摘要 目的探讨胸水沉渣包埋联合免疫组化方法在胸水转移性肺腺癌和胸膜恶性间皮瘤诊断及鉴别诊断中的应用价值。方法采用常规细胞涂片法和沉渣包埋联合免疫组化法对比62例患者胸水,免疫组化选用CEA、TTF-1、mesothelial cell(MC)、calretinin(CR)、vimentin、AE1/AE3和CK7抗体进行染色。结果常规涂片法诊断:转移性腺癌39例、恶性肿瘤细胞7例、可疑癌瘤细胞16例;沉渣包埋联合免疫组化法诊断:转移性腺癌54例、恶性间皮瘤8例。免疫组化示转移性腺癌CEA(81.5%)和TTF-1(81.5%)(+);恶性间皮瘤MC(87.5%)、CR(100%)和vimentin(100%)(+)。结论沉渣包埋联合免疫组化法在胸水转移性肺腺癌和胸膜恶性间皮瘤病理诊断分型方面明显优于常规细胞涂片法;CEA、TTF-1、MC、CR和vimentin抗体组合检测对胸水转移性肺腺癌与胸膜恶性间皮瘤的鉴别诊断具有重要意义。 Objective To discuss the value of the combined use of paraffin-embedded sediment sections and immunohistochemistry in differential diagnosis of metastasized adenocarcinoma from mesothelioma. Methods 62 cases were involved in this study. Cytological smears, sediment sections with CEA, TTF-1, mesothelial cell (MC) , calrentinin (CR) , vimentin, AEI/AE3, CK7 immunohistochemical assay were used. Results 39 cases of adenocarcinomas, 7 cases with malignant cells and 16 cases of undefined cells were diagnosed in cytological smears. 54 cases and 8 cases were definitely diagnosed as adenocarcinoma and mesothelioma, respectively, through sediment sections with immunohistochemical staining. The positive rate of CEA and TTF-1 in adenocarcinoma was 81.5% , 81.5% , respectively, whereas MC ( 87.5% ), CR ( 100% ) and vimentin ( 100% ), respectively, in mesothelioma. Conclusion The sediment sections combined with immunohistochemistry is more effective method in the differential diagnosis of malignant pleural fluid. Combined use of CEA, TTF-1, MC, CR and vimentin antibodies has a significant value in the differential diagnosis of adenocarcinoma from malignant mesothelioma.
出处 《诊断病理学杂志》 CSCD 北大核心 2014年第5期263-266,共4页 Chinese Journal of Diagnostic Pathology
关键词 沉渣包埋 免疫组化 转移性腺癌 恶性间皮瘤 Sediment embedding Immunohistochemistry Metastasized adenocarcinoma Mesothelioma
  • 相关文献

参考文献6

二级参考文献17

  • 1[3]Bateman AC,al-Talib RK,Newman T,et al.Immunohistochemical phenotype of malignant mesothelioma:predictive value of CA125and HBME-1 expression.Histopathology,1997,30(1):49-56.
  • 2[7]Ordonez NG.The immunohistochemical diagnosis of epithelial mesothelioma.Hum Pathol,1999,30(3):313-323.
  • 3[8]Khoor A,Whitsett JA,Stahlman MT,et al.Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma.Hum Pathol,1999,30(6):695-700.
  • 4Irani DR, Underwood RD, Johnson EH, et al. Malignant pleural effu-sions :a clinical cytopathologic study [J]. Arch Intern Med, 1987,147 (6) : 1133 -1136.
  • 5Alemdn C, Sanchez L, Alegre J, et al. Differentiating between malig-nant and idiopathic pleural effusions : the value of diagnostic procedures[J]. QJM, 2007, 100 (6) : 351 -359.
  • 6Porcel JM, Vives M. Etiology and pleural fluid characteristics of largeand massive effusions [J]. Chest, 2003, 124 (3): 978 -983.
  • 7Ikeda K, Tate G, Suzuki T, et al. Comparison of immunocytochemicalsensitivity between formalin - fixed and alcohol - fixed specimens revealsthe diagnostic value of alcohol - fixed cytocentrifuged preparations in ma-lignant effusion cytology [ J ]. Am J Clin Pathol, 2011, 136 ( 6 ):934 -942.
  • 8Bagheri R,Haghi SZ,Rahim MB,et al. Malignant pleural mesotheli-oma: clinicopathologic and survival characteristic in a consecutive seriesof40 patients [J]. Ann Thorac Cardiovasc Surg, 2011,17 (2):130 -136.
  • 9Renshaw AA, Dean BR, Antman KH, et al. The role of cytologicevaluation of pleural fluid in the diagnosis of malignant mesothelioma[J]. Chest, 1997,111 (1): 106-109.
  • 10Metintas M,Ak G,Dundar E,et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients withpleural effusions: a randomized, controlled trial [ J ]. Chest, 2010,137 (6) : 1362 -1368.

共引文献51

同被引文献107

引证文献17

二级引证文献101

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部